Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity

被引:83
作者
Zhou, YL [1 ]
Bosch, ML [1 ]
Salgaller, ML [1 ]
机构
[1] NW Biotherapeut Inc, Bothell, WA 98021 USA
关键词
dendritic cells; cancer vaccines; immunotherapy; cytotoxic T lymphocytes; antigen presenting cells; antigen presentation; neoplasm antigens; viral vaccines;
D O I
10.1097/00002371-200207000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immunotherapy of cancer is predicated on the belief that it is possible to generate a clinically meaningful antitumor response that provides patient benefit, such as improvement in the time to progression or survival. Indeed, immunotherapeutics with dendritic cells (DC) as antigen-presenting delivery vehicles for cell-based vaccines have already improved patient outcome against a wide range of tumor types (1-9). This approach stimulates the patient's own antitumor immunity through the induction or enhancement of T-cell immunity. It is generally believed that the activity of cytotoxic T lymphocytes (CTL), the cells directly responsible for killing the tumor cells in vivo, are directed by DC. Therefore, the goal of many current designs for DC-based vaccines is to induce strong tumor-specific CTL responses in patients with cancer. In practice, most studies for DC-based cancer vaccine development have focused on the development of methods that can effectively deliver exogenous tumor antigens to DC for cross-priming of CD8(+) T cells through the endogenous MHC class I processing and presentation pathway (10). To date, many methods have been developed or evaluated for the delivery of defined and undefined tumor antigens to DC. This review provides a brief summary on these methods, the techniques used in these methods, as well as the advantages and disadvantages of each method.
引用
收藏
页码:289 / 303
页数:15
相关论文
共 236 条
  • [1] Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model
    Akasaki, Y
    Kikuchi, T
    Homma, S
    Abe, T
    Kofe, D
    Ohno, T
    [J]. JOURNAL OF IMMUNOTHERAPY, 2001, 24 (02): : 106 - 113
  • [2] Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs
    Albert, ML
    Sauter, B
    Bhardwaj, N
    [J]. NATURE, 1998, 392 (6671) : 86 - 89
  • [3] Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
    Albert, ML
    Pearce, SFA
    Francisco, LM
    Sauter, B
    Roy, P
    Silverstein, RL
    Bhardwaj, N
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (07) : 1359 - 1368
  • [4] Amigorena S, 2000, MEDICINA-BUENOS AIRE, V60, P51
  • [5] Arnold-Schild D, 1999, J IMMUNOL, V162, P3757
  • [6] Arthur JF, 1997, CANCER GENE THER, V4, P17
  • [7] Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
    Ashley, DM
    Faiola, B
    Nair, S
    Hale, LP
    Bigner, DD
    Gilboa, E
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) : 1177 - 1182
  • [8] Anthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T-lymphocyte epitope from ovalbumin
    Ballard, JD
    Doling, AM
    Beauregard, K
    Collier, RJ
    Starnbach, MN
    [J]. INFECTION AND IMMUNITY, 1998, 66 (02) : 615 - 619
  • [9] Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo
    Ballard, JD
    Collier, RJ
    Starnbach, MN
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (22) : 12531 - 12534
  • [10] Immunobiology of dendritic cells
    Banchereau, J
    Briere, F
    Caux, C
    Davoust, J
    Lebecque, S
    Liu, YT
    Pulendran, B
    Palucka, K
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 : 767 - +